HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Atossa Therapeutics (NASDAQ:ATOS) and maintained a price target of $6.
June 28, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Atossa Therapeutics and maintained a price target of $6.
The reiteration of a Buy rating and the maintenance of a $6 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100